Latest News

Each news article below shows only part of the news story. To view the full story, click on Read More below the story. 

  • February 01, 2021 10:25 AM | Becca Liebers (Administrator)

    Practice Advisories

    New Committee Opinions

    New Practice Bulletins

    More from ACOG

  • February 01, 2021 8:10 AM | Becca Liebers (Administrator)


    The New York Times (1/31, Caron) reported researchers found that pregnant women transfer SARS-CoV-2 antibodies to their fetuses and transfer “more antibodies to their babies if they are infected earlier in their pregnancies.” The findings (1/29) were published in JAMA Pediatrics. Dr. Denise Jamieson, an obstetrician at Emory University and a member of ACOG’s Covid expert group, said the placenta is a complex organ that has been understudied and “What we really want to know is, do antibodies from the vaccine efficiently cross the placenta and protect the baby, the way we know happens in influenza and pertussis.” Dr. Mark Turrentine, a member of ACOG’s Covid expert group, said: “It’s plausible that the Covid vaccine will offer protection to both pregnant mothers and their infants. To me, this study highlights that inclusion of pregnant women in clinical trials such as the Covid-19 vaccine is essential, particularly when the benefit of vaccination is greater than the potential risk of a life-threatening disease.”

    CIDRAP (1/29, Van Beusekom) reported the researchers found in the study that “SARS-CoV-2 antibodies transferred across the placenta in 87% of pregnant women who had COVID-19 at some point, suggesting that newborns of seropositive mothers may have some protection against the novel coronavirus at birth.” 
  • January 27, 2021 9:48 AM | Becca Liebers (Administrator)

    Washington, DC – The American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) are aware of the World Health Organization’s (WHO) recommendation to withhold COVID-19 vaccines from pregnant individuals unless they are at high risk of exposure. ACOG and SMFM continue to stress that both COVID-19 vaccines currently authorized by the U.S. Food and Drug Administration should not be withheld from pregnant individuals who choose to receive the vaccine. ACOG’s and SMFM’s current guidance on the COVID-19 vaccine in pregnant patients remains in place.

    Despite efforts by ACOG and SMFM to advocate for their inclusion, clinical trials that informed the emergency use authorization (EUA) of the vaccines did not include pregnant individuals. However, preliminary developmental and reproductive toxicity (DART) studies for both the Pfizer-BioNtech and Moderna vaccines are encouraging, with no safety signals reported. DART animal studies provide the first safety data to help inform the use of these vaccines in pregnancy until there are more data in this specific population. These studies do not indicate any adverse effects on female reproduction or fetal/embryonal development. ACOG and SMFM strongly urge manufacturers and federal agencies to collect and report data regarding the use of these vaccines in pregnancy.

    Read more. 

  • January 25, 2021 9:11 AM | Becca Liebers (Administrator)

    APAOG is now accepting partner applications for our women's health resource center. If you want to increase your exposure to PAs who practice in women's health, this opportunity is for you. Our premium and supporting partner options provide a range of benefits at great prices. Contact our office with any questions.

    Visit our Partners webpage for more information about this opportunity!

  • January 23, 2021 9:09 AM | Becca Liebers (Administrator)

    Today is #MaternalHealthAwarenessDay and APAOG is observing with our fellow women’s health professionals in order to improve maternal health outcomes and eliminate inequities for our patients and for moms across the country. #123ForMoms #PAs #OBGYN #WomensHealth #APAOG #ACOG 

  • January 04, 2021 9:56 AM | Becca Liebers (Administrator)

    Walk Through Steps of Administering LARC in CME
    Nisha McKenzie, PA-C, CSC, NCMP, IF and Deanna Bridge Najera, PA-C

    Nisha McKenzie, PA-C, CSC, NCMP, IF, founder of Women’s Health Collective in Grand Rapids, Michigan, and Deanna Bridge Najera, PA-C, clinician consultant in Carroll County, Maryland, team up to talk about Long-Acting Reversible Contraception (LARC). They are also the featured instructors in LARC CME available now on AAPA’s Learning Central. The CME covers how LARC use comes up and is discussed in real interactions with patients. It includes real-life scenarios often lacking in training but are quite helpful for clinical practice. Here, McKenzie and Najera share tips on LARC and treating patients.

    Read more.

  • December 16, 2020 10:04 AM | Becca Liebers (Administrator)

    “As an OBGYN PA for over 10 years, I have had the privilege to work in a field that I am passionate about. Being a PA has allowed me to transition between labor and delivery, high risk obstetrics, gynecology, minimally invasive surgery, and outpatient settings. We are primary care, medical, and surgical subspecialties in one. APAOG has provided in-depth webinars of necessary topics and connections with successful PAs in the field. Without these benefits it would have been challenging to progress in OBGYN. Now, with a thorough understanding of the opportunities and barriers to PAs in women's health, we have come together to offer even more for our members. We are looking forward to a larger community of like-minded PAs to improve our presence in obstetrics and gynecology.”
    - Melissa Rodriguez, PA-C

  • December 14, 2020 8:01 AM | Becca Liebers (Administrator)

    ACOG | Published December 13, 2020

    This Practice Advisory was developed by the American College of Obstetricians and Gynecologists’ Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group in collaboration with Laura E. Riley, MD; Richard Beigi, MD; Denise J. Jamieson, MD, MPH; Brenna L. Hughes, MD, MSc; Geeta Swamy, MD; Linda O’Neal Eckert, MD; Cynthia Gyamfi-Bannerman, MD, MSc; and Mark Turrentine, MD.

    Summary of Key Information and Recommendations 

    COVID-19 vaccine development and regulatory approval are rapidly progressing. Thus, information and recommendations will evolve as more data are collected about these vaccines and their use in specific populations. This Practice Advisory is intended to be an overview of currently available COVID-19 vaccines and guidance for their use in pregnant and lactating patients.

    • On December 11, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNtech mRNA vaccine (BNT162b2) for use in individuals age 16 years and older as a 2-dose regimen given 3 weeks apart. This vaccine has shown to be 95% effectivat preventing COVID-19 illness after the second dose.
    • On December 12, 2020, after an explicit, evidence-based review of all available data, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19 illness. 
    • ACOG recommends that COVID-19 vaccines should not be withheld from pregnant individuals who meet criteria for vaccination based on ACIP-recommended priority groups. 
    • COVID-19 vaccines should be offered to lactating individuals similar to non-lactating individuals when they meet criteria for receipt of the vaccine based on prioritization groups outlined by the ACIP.
    • Individuals considering a COVID-19 vaccine should have access to available information about the safety and efficacy of the vaccine, including information about data that are not available. A conversation between the patient and their clinical team may assist with decisions regarding the use of vaccines approved under EUA for the prevention of COVID-19 by pregnant patients.  Important considerations include:
      • the level of activity of the virus in the community 
      • the potential efficacy of the vaccine
      • the risk and potential severity of maternal disease, including the effects of disease on the fetus and newborn 
      • the safety of the vaccine for the pregnant patient and the fetus.
    • While a conversation with a clinician may be helpful, it should not be required prior to vaccination, as this may cause unnecessary barriers to access.
    • Vaccines currently available under EUA have not been tested in pregnant women. Therefore, there are no safety data specific to use in pregnancy. See details about the Food and Drug Administration’s (FDA) EUA process below.
    • Pregnancy testing should not be a requirement prior to receiving Pfizer-BioNTech vaccine. 
    • Pregnant patients who decline vaccination should be supported in their decision. Regardless of their decision to receive or not receive the vaccine, these conversations provide an opportunity to remind patients about the importance of other prevention measures such as hand washing, physical distancing, and wearing a mask. 
    • Expected side effects should be explained as part of counseling patients, including that they are a normal part of the body’s reaction to the vaccine and developing antibodies to protect against COVID-19 illness.
    • The mRNA vaccines are not live virus vaccines, nor do they use an adjuvant to enhance vaccine efficacy. These vaccines do not enter the nucleus and do not alter human DNA in vaccine recipients. As a result, mRNA vaccines cannot cause any genetic changes.

    Read more.

  • December 09, 2020 10:02 AM | Becca Liebers (Administrator)

    "Nationwide a small percent of PAs specialize in Obstetrics & Gynecology, therefore, being part of an Ob/Gyn PA network is invaluable. APAOG not only offers networking opportunities, but also monthly newsletters with up-to-date content, and quarterly webinars for CME credit to members. As a member of APAOG I have been able to enhance my learning and education within women's health as well as become informed on guidelines and new practices."
    Melanie A. Jacobs, MMS, PA-C

  • December 07, 2020 8:58 AM | Becca Liebers (Administrator)

    CNN | LaMotte

    The stress a woman feels during pregnancy can affect the developing brain of her unborn child as documented on fetal brain scans, according to a new study published Monday in the medical journal JAMA Open Network.

    Fetuses of expectant moms with higher anxiety levels were more likely to have weaker connections between two brain areas involved in executive and higher cognitive functions and stronger connections between parts of the brain connected to emotional and behavioral controls.

    The study echoes other recent research that has found a direct impact of maternal stress on a baby's future development.

    Read more.

Powered by Wild Apricot Membership Software